What question did this study set out to answer?

To evaluate the real-world effectiveness of sutimlimab in patients with cold agglutinin disease (CAD).

December 8, 2025BloodOpen Access

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

View Full Paper

Ask AI

Bookmark

Authors

International study shows sutimlimab improves hemoglobin and reduces hemolysis in cold agglutinin disease, suggesting effective real-world treatment.

To evaluate the real-world effectiveness of sutimlimab in patients with cold agglutinin disease (CAD).
Evaluated 54 CAD patients treated with sutimlimab via post-trial access or compassionate use programs.
Collected baseline and follow-up data on medical history, treatments, and laboratory parameters at multiple time points.
Assessed responses based on hemoglobin increases and other clinical outcomes over a median follow-up of 28 months.
Hemoglobin increased significantly over time, with 78-86% response rates observed at various follow-up points.
Most patients became transfusion-independent; only two discontinued treatment due to lack of response.
Sutimlimab confirmed effective for improving anemia and hemolysis in over 70% of real-world patients.

Visco et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

International study shows sutimlimab improves hemoglobin and reduces hemolysis in cold agglutinin disease, suggesting effective real-world treatment.